Celldex Highlights Phase 3 Barzolvolimab Data With Complete Response Near 54% at 24 Weeks in CSU
Market Chameleon (Tue, 22-Sep 11:36 AM)
Celldex reports Phase 3 barzolvolimab CSU wins as complete response rates approach 54% by Week 24
Market Chameleon (Tue, 22-Sep 7:28 AM)
